Senseonics Prices $80M Offering of 8M Shares and 8M Warrants
Senseonics priced an $80 million underwritten public offering of 8 million common shares at $5.00 and 8 million pre-funded warrants at $4.999 per share, with underwriters granted a 30-day option on 2.4 million additional shares. Net proceeds will fund the Eversense 365 launch, pipeline development and general corporate purposes.
1. Offering Details
Senseonics issued 8 million common shares at $5.00 each and 8 million pre-funded warrants at $4.999 per warrant, reflecting a $0.001 exercise price for each warrant. Underwriters received a 30-day option to purchase up to 2.4 million additional shares at the offering price. Pre-funded warrants will not be listed on any exchange.
2. Expected Closing and Proceeds
The offering is expected to close on May 4, 2026, subject to customary closing conditions. Gross proceeds are anticipated to total $80 million before underwriting discounts, commissions and estimated offering expenses.
3. Use of Proceeds and Strategic Impact
Senseonics plans to deploy net proceeds to support the ongoing launch of its Eversense 365 continuous glucose monitoring system, advance development of pipeline products, and bolster working capital and general corporate purposes.